| LAKEFRONT BIOTHERAPEUTICS (GALAPAGOS) |
| Belgien |
| Gesundheit |
| BE0003818359 / A0EAT9 |
| GXE (Frankfurt) |
| FRA:GXE, ETR:GXE, GXE:GR |
| AEX |
| https://lakefrontbio.com/ |
|
Lakefront Biotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of small molecule therapies targeting unmet medical needs. Headquartered in Belgium, it operates in the healthcare sector, leveraging advance..
>Volltext.. |
| 1994.53 Mio. EUR |
| -191.82 Mio. EUR |
| 952.75 Mio. EUR |
| - |
| 818.2 Mio. EUR |
| 12.42 EUR |
| 3.19 Mio. EUR |
| 97.29 Mio. EUR |
| -143.69 Mio. EUR |
| 45.17 |
| 223.08% |
| - |
| - |
| - |
| - |
| - |
| LAKEFRONT BIOTHERAPEUTICS, LAKEFRONT BIO, LAKEFRONT BIOTHERAPEUTIC, GALAPAGOS NV |
| 16.11.26 |
|